The Ulcerative Colitis (UC) treatment market is already undergoing radical change as new, safer products that slow disease progression have come to market or will be launched in the next few years. While 5-ASA and corticosteroids will remain the backbone of treatment, new products that delay progression to steroid treatment or surgery are vying for market space.
Ulcerative Colitis: Dawn of the integrin inhibitors is a comprehensive report from FirstWord packed with the candid opinions of 12 leading North American and European KOLs that present business-critical insights for pharma. Get insights on what they think about current treatment options and the competing clinical and cost benefits that influence their decisions.
When and why will clinicians use these new therapies? Will Entyvio dominate as experience grows? Will the advantages of Genentech’s etrolizumab gate crash the market? Will naturally derived low toxicity LT-02 find favour with patients? When is combination therapy best, and in what circumstances? Ulcerative Colitis: Dawn of the integrin inhibitors answers these questions and more.
| || |
Answers to Critical Questions
- What is the current clinical view of Entyvio and what is limiting its wider adoption?
- What KOL insights hold lessons for Genentech as it plans for the launch of etrolizumab?
- What opportunities may there be for Simponi and Humira in the expanding paediatric UC sector?
- What clinical trials could help widen the use of Uceris/Cortiment as both an induction and maintenance therapy?
- Lipid Therapeutics’ LT-02 is a safe, naturally derived treatment which may be favoured by patients. But what trial, regulatory and production hurdles must it overcome?
- Pfizer’s tofacitinib is recognised as an effective UC treatment so why do KOLs see it as a last line therapy?
- What treatment niches do KOLs think InDex Pharmaceuticals and Atlantic Healthcare could respectively carve out for Kappaproct and alicaforsen?
- Combination therapy is being investigated in all stages of UC – what drug combinations do KOLs view positively, and why, and are there implications for manufacturers?
Update Bulletins Offer Ongoing Benefits
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
- Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, December 2014.
- You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date
Therapy Trends reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.